ArticleFrontiers in molecular biosciences2026
Identifying pyroptosis-related lncRNAs to predict prognosis and immune regulation in hepatocellular carcinoma.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy is often effective for treating hepatocellular carcinoma (HCC) and is widely used clinically, with variable effectiveness among individuals. Purpose: In this study, we aimed to develop a predictive signature from eight pyroptosis-related long non-coding RNAs (PRlncRNAs) for survival forecasting in HCC patients and immunotherapy evaluations. Methods: To assess the prognostic performance of the risk signature, we performed the following analyses: Kaplan-Meier survival analysis, receiver operator characteristics analysis, and nomogram construction. Results: The results showed that individuals within the high-risk cohort exhibited unfavorable prognosis, with the risk score acting as an independent predictor of prognosis. The PRlncRNAs in the high-risk cohort were significantly gathered in the immune-related signaling pathways; gene set enrichment analysis (GSEA) and single-sample GSEA showed that their functional activities were reliant on the immune cells, inhibitory immune checkpoints, and cytokines. Furthermore, we confirmed that downregulation of LINC00942 (a risk factor) expression increased pyroptosis levels and promoted infiltration of CD3 in HCC, while si-AC009283.1 group (a protective factor) exerted opposite effects Conclusion: This risk signature developed using eight PRlncRNAs exhibits high reliability for predicting the prognosis of HCC patients and assessing their immune status, emphasizing their crucial roles in guiding immunotherapy and crafting precise treatments for the benefit of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.